Abpro Holdings, Inc. (ABPO)
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Abpro Holdings, Inc.
- 0.3%
- 15.8K
- 1.00
Float 5.01M · Signal8 dilution snapshot · Aug 14, 2026
The cost to borrow ABPO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 19.4%
- 400
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 15.8K sh |
| Oct 15, 2026 | 16.1K sh |
| Sep 30, 2026 | 16.1K sh |
| Sep 15, 2026 | 12.2K sh |
| Aug 31, 2026 | 15.2K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 29, 2026 | 400 sh |
| Jun 17, 2026 | 747 sh |
| Jun 10, 2026 | 11.7K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 19.4% |
| Nov 16, 2026 | 12.4% |
| Nov 13, 2026 | 61.8% |
| Nov 12, 2026 | 10.3% |
| Nov 11, 2026 | 80.7% |
130 calendar days requested; 55 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for ABPO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 15,840 ABPO shares were sold short (0.32% of a 5.01M-share float, 1.00 days to cover).